目 录 | | 每日报告精选（2026-02-25 09:00——2026-02-26 15:00） | 2 | | --- | --- | --- | |  | 海外策略研究：《关税、地缘与 AI 叙事扰动，春节多数资产收涨》2026-02-25 2 | | |  | 行业跟踪报告：社会服务业《春节消费高景气，关注性价比、情绪价值和体验》2026-02-26 2 | | |  | 行业事件快评：其他小金属《津巴布韦收紧锂精矿出口，供给扰动再现》2026-02-26 3 | | |  | 行业跟踪报告：房地产《期待更强政策干预，推动供需再平衡》2026-02-26 4 | | |  | 行业专题研究：医药《从靶点到管线，FXI 引领抗凝产业新变革》2026-02-25 5 | | |  | 行业跟踪报告：汽车《1 月重卡"开门红"，同环比均有增长》2026-02-25 6 | | |  | 行业跟踪报告：房地产《沪"新七条"发布，小阳春可期》2026-02-25 6 | | |  | 行业专题研究：商业银行《大型银行短贷显著增加，中小银行信贷增长放缓》2026-02-25 7 | | |  ...

公 司 研 究 新拓电子布领域，半导体无尘耗材亦高增 聚杰微纤(300819) ——聚杰微纤更新 | [姓名table_Authors] | 电话 | 邮箱 | 登记编号 | | --- | --- | --- | --- | | 花健祎(分析师) | 0755-23976858 | huajianyi@gtht.com | S0880521010001 | | 盛开(分析师) | 021-23154510 | shengkai@gtht.com | S0880525040044 | | 巫恺洋(分析师) | 0755-23976666 | wukaiyang@gtht.com | S0880525080008 | 本报告导读： 公开工商信息显示公司通过收购拓展电子布领域，设备灵活升级能力或是特色，公 司半导体无尘擦拭耗材也在快速发展阶段。 投资要点： 风险提示：原材料成本暴涨，下游需求不及预期，竞争格局恶化。 | [Table_Finance] 财务摘要(百万元) | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- ...

公 司 研 究 新拓电子布领域，半导体无尘耗材亦高增 聚杰微纤(300819) ——聚杰微纤更新 | [姓名table_Authors] | 电话 | 邮箱 | 登记编号 | | --- | --- | --- | --- | | 花健祎(分析师) | 0755-23976858 | huajianyi@gtht.com | S0880521010001 | | 盛开(分析师) | 021-23154510 | shengkai@gtht.com | S0880525040044 | | 巫恺洋(分析师) | 0755-23976666 | wukaiyang@gtht.com | S0880525080008 | 本报告导读： 公开工商信息显示公司通过收购拓展电子布领域，设备灵活升级能力或是特色，公 司半导体无尘擦拭耗材也在快速发展阶段。 投资要点： 风险提示：原材料成本暴涨，下游需求不及预期，竞争格局恶化。 | [Table_Finance] 财务摘要(百万元) | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- ...

公 司 研 究 步入成长新阶段，高端装备与机器人共驱 五洲新春(603667) 五洲新春跟踪报告 | [姓名table_Authors] | 电话 | 邮箱 | 登记编号 | | --- | --- | --- | --- | | 徐强(分析师) | 010-83939805 | xuqiang@gtht.com | S0880517040002 | | 马菁菁(分析师) | 021-23185627 | majingjing@gtht.com | S0880525040118 | 本报告导读： 公司 2025 前三季度业绩呈现稳健增长，毛利率提升明显。通过前瞻布局机器人丝杠 与汽车智驾核心部件，打开新的长期成长空间。 投资要点： | [Table_Finance] 财务摘要(百万元) | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入 | 3,106 | 3,265 | 3,735 | 4,315 | 5,011 | | (+/-)% | -2.9% | 5.1% | 14.4% | ...

[Table_Report] 相关报告 期待更强政策干预，推动供需再平衡 [Table_Industry] 房地产 ——中国城市运行周期跟踪（2025.Q4） | [姓名table_Authors] | 电话 | 邮箱 | 登记编号 | | --- | --- | --- | --- | | 涂力磊(分析师) | 021-23185710 | tulilei@gtht.com | S0880525040101 | | 谢皓宇(分析师) | 010-83939826 | xiehaoyu@gtht.com | S0880518010002 | | 白淑媛(分析师) | 021-38675923 | baishuyuan@gtht.com | S0880518010004 | 本报告导读： 2025 年 4Q 市场整体表现出成交量乏力、价格环比继续回落以及库存上涨、去化压 力持续增大特点。考虑一、二线城市出清周期均呈现持续攀升态势，且达到 2023 年以来最高水平，市场需要更长时间或更强力的政策干预来推动再平衡。 投资要点： 房地产《沪"新七条"发布，小阳春可期》2026.02.25 房地产《第 8 周成交回落、 ...

Investment Rating - The report assigns an "Accumulate" rating to the company [1][6]. Core Insights - The report highlights the strong innovative research and development capabilities of the company, which is entering a harvest period for innovative drugs while establishing an international business development ecosystem with several significant collaborations [2][10]. - The company is expected to achieve a compound annual growth rate (CAGR) in earnings per share (EPS) of 48% from 2025 to 2027, with a target price set at HKD 16.58 [10]. Financial Summary - Total revenue is projected to be RMB 31,450.11 million in 2023, with a slight increase of 1.7% year-on-year. However, a decline of 7.8% is expected in 2024, followed by a gradual recovery in subsequent years [4][11]. - Gross profit is forecasted to be RMB 22,177 million in 2023, with net profit expected to be RMB 5,873 million, reflecting a decrease of 3.6% [4][11]. - The price-to-earnings (P/E) ratio is projected to be 18.26 in 2023, increasing to 24.78 in 2024 before declining to 16.80 in 2025 [4][11]. Pipeline Overview - The company has a leading position in the oncology pipeline, with SYS6010 being the fastest progressing EGFR ADC globally, and multiple early-stage assets expected to report data in 2026 [10][14]. - In the weight loss and metabolic fields, the company has established a leading position domestically, with a strategic collaboration with AstraZeneca to develop innovative long-acting peptide drugs [10][24]. - The company has secured a total deal value of USD 18.5 billion from collaborations, including upfront payments and potential milestone payments [10][24]. Clinical Development - The report outlines several key clinical trials, including SYS6010, which is in Phase III for EGFRm NSCLC, and various other assets in different stages of development [18][20]. - The company is actively recruiting for multiple trials, with significant data expected to be released in 2026 [18][20]. Market Position - The company is positioned as a leader in the domestic market for small nucleic acid technology, with a strong pipeline in siRNA [10][24]. - The report emphasizes the company's competitive edge in the next-generation weight loss drugs and cardiovascular metabolic therapies, supported by strategic partnerships with multinational corporations [10][24].

Investment Rating - The report assigns an "Accumulate" rating to the company [1][6]. Core Insights - The report highlights the strong innovation and R&D capabilities of the company, which is entering a harvest period for innovative drugs and has established an international business development ecosystem with several significant licensing agreements [2][10]. - The company is expected to achieve a significant increase in EPS from 0.37 in 2024 to 0.75 in 2025, with a projected growth rate of 48% [10]. - The target price for the company is set at 16.58 HKD, reflecting a favorable valuation based on comparable company analysis [10]. Financial Summary - Total revenue is projected to be 31,450.11 million RMB in 2023, with a slight increase of 1.7% [4]. - Net profit is expected to decrease by 3.6% in 2023, followed by a significant recovery of 47.5% in 2025 [4]. - The company’s PE ratio is forecasted to decrease from 18.26 in 2023 to 12.34 in 2026, indicating an improving valuation over time [4]. Pipeline Overview - The company has a leading position in the oncology pipeline, particularly with SYS6010, which is the fastest progressing EGFR ADC globally, with multiple early-stage assets expected to report data in 2026 [10][16]. - In the weight loss and metabolic areas, the company has established a leading position domestically and has signed a strategic collaboration with AstraZeneca for the development of innovative long-acting peptide drugs [10][24]. - The company has a robust pipeline in the small nucleic acid technology sector, positioning it as a leader in the domestic siRNA market [10][24]. Business Development and International Strategy - The company is making steady progress in its international strategy, with ongoing collaborations with AstraZeneca and other multinational corporations, reflecting its competitive edge in innovative drug development [10][24]. - The company is expected to continue achieving external licensing agreements, with over 20 innovative drug assets entering clinical stages annually [10][24].

| [Table_Finance] 财务摘要(百万元) | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入 | 1,206 | 1,525 | 1,830 | 2,398 | 3,107 | | (+/-)% | 4.6% | 26.4% | 20.0% | 31.1% | 29.5% | | 净利润(归母) | 180 | 225 | 275 | 354 | 442 | | (+/-)% | 19.6% | 25.1% | 22.1% | 28.9% | 24.7% | | 每股净收益(元) | 0.75 | 0.94 | 1.14 | 1.47 | 1.83 | | 净资产收益率(%) | 5.8% | 7.0% | 7.9% | 9.4% | 10.7% | | 市盈率(现价&最新股本摊薄) | 162.92 | 130.23 | 106.69 | 82.78 | 66.37 | 港交所聆讯通过，全球化战略加速 兆威机电(003021) 公司赴港上市聆讯通过点评 | [姓名tabl ...

津巴布韦收紧锂精矿出口，供给扰动再现 [Table_Industry] 其他小金属 碳酸锂行业事件点评 | [姓名table_Authors] | 电话 | 邮箱 | 登记编号 | | --- | --- | --- | --- | | 李鹏飞(分析师) | 010-83939783 | lipengfei2@gtht.com | S0880519080003 | | 魏雨迪(分析师) | 021-38674763 | weiyudi@gtht.com | S0880520010002 | 本报告导读： 津巴布韦禁止锂精矿出口，在短期对全球锂的供给造成较大扰动，预期锂价偏强运 行。 [Table_Report] 相关报告 其他小金属《指标再度收紧，供给刚性挺价》 2025.04.23 其他小金属《开采指标下调，钨矿供应偏紧》 2024.03.20 投资要点： 证 券 研 究 报 告 请务必阅读正文之后的免责条款部分 股 票 研 究 行 业 事 件 快 评 股票研究 /[Table_Date] 2026.02.26 [Table_Summary] 维持"增持"评级。碳酸锂行业供给偏紧，库存持续去化，津巴布 韦禁 ...

股票研究 /[Table_Date] 2026.02.26 [Table_Industry] 资本货物/工业 港交所聆讯通过，全球化战略加速 兆威机电(003021) 公司赴港上市聆讯通过点评 | [姓名table_Authors] | 电话 | 邮箱 | 登记编号 | | --- | --- | --- | --- | | 肖群稀(分析师) | 0755-23976830 | xiaoqunxi@gtht.com | S0880522120001 | | 刘麒硕(分析师) | 0755-23976666 | liuqishuo@gtht.com | S0880525080005 | 本报告导读： 公司通过港交所主板上市聆讯，全球化战略加速。前瞻布局机器人赛道，汽车、电 子业务需求旺盛，看好公司业绩增长。 投资要点： | [Table_Finance] 财务摘要(百万元) | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入 | 1,206 | 1,525 | 1,830 | 2,398 ...